AM966 is primarily utilized in research settings to study its effects on cannabinoid receptors, particularly the CB1 receptor. It acts as a potent and selective antagonist at CB1, with minimal activity at CB2, making it valuable for investigating the endocannabinoid system and its role in various physiological processes. Researchers use AM966 to explore potential therapeutic applications, such as pain management, inflammation, and neurological disorders. Its high selectivity and efficacy in binding to the CB1 receptor make it a useful tool for understanding receptor signaling pathways and developing targeted treatments. Additionally, AM966 is employed in preclinical studies to assess its pharmacological properties and potential side effects, contributing to the broader understanding of cannabinoid-based therapies.